Jeffrey Leiden

Last updated
Jeffrey Leiden
Jeffrey Leiden Portrait.jpg
Born
Glencoe, Illinois
NationalityAmerican
Alma mater University of Chicago
Occupation(s)Executive Chairman, Vertex Pharmaceuticals
Organizations
Board member of
Awards
Website Jeffrey Leiden

Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. [1] He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020. [2] [3]

Contents

Early life

Leiden grew up in Glencoe, a suburb north of Chicago. His mother was a primary school teacher, and his father was a clinical psychologist with a PhD in psychology. He has one sister. His grandparents on his mother’s side were Russian immigrants. At ten years old he learned to scuba dive, and by eleven he was a certified scuba instructor. [4]

Education

Leiden attended a progressive public school in Glencoe, IL called North School which had a special self-paced learning program. In elementary school Leiden skipped second grade and started the University of Chicago after his junior year at New Trier East High School, at the age of 15. [4]

He received his bachelor's degree in biological sciences at age 18, a Ph.D. in virology at age 21 and his M.D. at age 23 from the University of Chicago, where he later became Chief of Cardiology. [5] [4] He was elected to several honors societies, including Phi Beta Kappa and Alpha Omega Alpha. [6] Between 1982 and 1987, Leiden was a clinical fellow in cardiology at the Brigham and Women’s Hospital, the Harvard Medical School and a postdoctoral fellow in medicine at the Dana–Farber Cancer Institute. [7]

Career

In 1987, Leiden was appointed assistant professor of medicine and assistant investigator in the Howard Hughes Medical Institute at the University of Michigan in Ann Arbor. [8]

In 1992, Leiden moved to the University of Chicago as the Rawson Professor of Medicine and Pathology and chief of the Division of Cardiology. [9]

In 1996, Leiden, along with Elizabeth and Gary Nabel founded Cardiogene, a gene therapy company, which was subsequently acquired by Boston Scientific. [10]

In 1999, Leiden was appointed the Elkin Blout Professor of Biological Sciences at the Harvard School of Public Health and professor of medicine at the Harvard Medical School. [7]

Leiden moved to Abbott Labs in June 2000, as senior vice president and chief scientific officer. Later that year, he was promoted to president and chief operating officer and oversaw all aspects of the company’s global pharmaceutical business, where he led the development and launch of Kaletra and Humira. [11] [12]

In 2006, Leiden joined Clarus Ventures as a managing director. [13] At Clarus, Leiden founded and chaired the boards of Lycera Corporation and Variation Biotechnologies, and served as chairman of the board of TyRx, Inc., which was subsequently acquired by Medtronic (NYSE :  MDT). [14]

Vertex

Leiden served as chairman, president and chief executive officer of Vertex from 2012 to 2020. Under his leadership, Vertex developed and launched Kalydeco, Orkambi, Symdeko and Trikafta – the first medicines to treat the underlying cause of cystic fibrosis. [15] The FDA approved Trikafta on October 21, 2019. [16]

In 2015 Leiden established a collaboration between Vertex and CRISPR Therapeutics that led to the discovery and development of CTX001, the first gene editing treatment to show curative potential for two human genetic diseases, sickle cell disease and beta thalassemia. [17] [18] [19]

In 2015 Vertex shareholders voted to recommend reducing Leiden's compensation from its 2014 estimated figure of US$48.5 million. By 2017 his earnings totaled approximately US$17.3 million. [20] Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. [21] [22]

On October 24, 2019, Vertex reached an agreement with NHS England for all currently licensed Vertex cystic fibrosis medicines, [23] [24] [25] having previously reached similar agreements with countries including Scotland, Ireland and France. [26] [27] While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020. [28]

On April 1, 2020, Leiden transitioned to the role of executive chairman. He was succeeded by Reshma Kewalramani, who was previously the company's chief medical officer. Leiden will serve as executive chairman until April 2024. [29] [30] [31]

Boards and awards

He is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation and the Association of American Physicians. [32] [33] He currently serves as a director of the Massachusetts Mutual Life Insurance Company, and was the former vice chairman of Shire Pharmaceuticals and was formerly a director of PathAI, Millennium Pharmaceuticals, Abbott Labs, Quest Diagnostics, and TAP Pharmaceuticals. [7] [34] Leiden is also the chairman of Casana, a home health monitoring company. [35] In May 2022 Leiden was appointed as Chairman of the Board of Odyssey Therapeutics, a company developing novel medicines for cancer and auto-immune disease. [36]

Leiden was named a Crain’s Chicago Business 40 Under 40 in 1994; and served as a member of the NHLBI Board of Scientific Counselors between 1994 and 1999. [7] [37] In 2000, he was president of the American Society for Clinical Investigation. [38]

In 2017, Ernst and Young named Leiden an Entrepreneur of the Year in Life Sciences. [39] In 2018, the Massachusetts Biotechnology Council awarded Leiden the Henri A. Termeer Innovative Leadership Award; and the Greater Boston Chamber of Commerce named Leiden to the Academy of Distinguished Bostonians. [40] [41] Leiden was also named one of Boston Business Journal’s Power 50 for several years, including most recently in 2022. [42] [43] In 2018 and 2020, he was named as part of Boston Magazine’s 100 Most Influential People in Boston [44] and was honored as a New Englander of the Year by the New England Council. [45] [46] In 2018 he was named “Best Biopharma CEO” by STAT News. [47] In December 2020 Jeffrey Leiden was honored with the Forbes Lifetime Achievement in BioPharma Award at the 2020 Forbes Healthcare Summit. [48]

Leiden also serves as co-chairman of the Massachusetts’s Governor’s Digital Healthcare Council and the Governor’s STEM Advisory Council. [49] [50]

Leiden was ranked 13th on Forbes' list of most innovative leaders for 2019, the highest-ranking leader in the healthcare/biotech sector. [51]

He is trustee of the Boston Symphony Orchestra. [52]

He is also chairman of the board of the Massachusetts Competitive Partnership. [53]

Leiden is a member of the MIT Presidential CEO Advisory Board. [54]

In November 2022 Leiden was named as one of several strategic advisors for the newly launched Life Sciences Private Capital, a private equity division of J.P. Morgan. [55]

He is a director of the Massachusetts Competitive Partnership (MACP) and previously served as chair from January 2020 to December 2022. [56] [57]

Philanthropy

In December 2017, Leiden and his wife Lisa established a professorship in translational medicine at the Brigham and Women’s Hospital and Harvard Medical School. [58] The Leidens are also major donors to the Museum of Fine Arts, Boston, Ariadne Labs and the Bottom Line Foundation. [12] [59]

Related Research Articles

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Venture philanthropy is a type of impact investment that takes concepts and techniques from venture capital finance and business management and applies them to achieving philanthropic goals. The term was first used in 1969 by John D. Rockefeller III to describe an imaginative and risk-taking approach to philanthropy that may be undertaken by charitable organizations.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Arcturus Therapeutics is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

<span class="mw-page-title-main">Editas Medicine</span> Discovery-phase pharmaceutical company

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

<span class="mw-page-title-main">Eve Slater</span> American physician (born 1945)

Eve Elizabeth Slater is an American physician who served as the United States Assistant Secretary for Health and Human Services under President George W. Bush from 2002 to 2003. Slater received her B.A from Vassar College in 1967 and M.D. from the Columbia University College of Physicians and Surgeons in 1971. She completed residency in internal medicine and fellowship in cardiology at the Massachusetts General Hospital, Boston, MA.In 1976, she was appointed the Chief Resident in Medicine at Massachusetts General Hospital, the first woman to appointed to this position. Dr. Slater is currently Professor of Clinical Medicine at Columbia Vagelos College of Physicians and Surgeons (P&S), where she has taught for over 35 years. She is board certified in internal medicine and cardiology and a fellow of the American College of Cardiology.(FACC). At MGH, she led the Hypertension Unit, as Assistant Professor of Medicine. Harvard Medical School.

<span class="mw-page-title-main">Intellia Therapeutics</span> Biotechnology company

Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

<span class="mw-page-title-main">Joshua Boger</span> Organic chemist and the founder of Vertex Pharmaceuticals

Joshua S. Boger is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design. Drugs developed include amprenavir, an HIV protease inhibitor; telaprevir, a protease inhibitor for treatment of hepatitis C; and Kalydeco, for the treatment of cystic fibrosis. In 2003, Vertex was listed as one of forty worldwide Technology Pioneers by the World Economic Forum. As of 2012, Boger became executive chairman of Alkeus Pharmaceuticals.

<span class="mw-page-title-main">Tezacaftor</span> Chemical compound

Tezacaftor is a drug used for the treatment of cystic fibrosis (CF) in people six years and older, who have a F508del mutation, the most common type of mutation in the CFTR gene. It is sold as a fixed-dose combination with ivacaftor under the brand name Symdeko. It was approved by the U.S. FDA in 2018. The combination of elexacaftor, tezacaftor, and ivacaftor is being sold as Trikafta.

<span class="mw-page-title-main">ProQR</span> Dutch biotechnology company

ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (EU), is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.

Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval in December 2023.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

Paul Adrian Negulescu is an American–Romanian cell biologist. He is the Senior Vice President and Site Head of the San Diego Research Center of American pharmaceutical company Vertex Pharmaceuticals. He received the 2022 Shaw Prize in Life science and medicine, together with Michael J. Welsh, for their work that uncovered the etiology of cystic fibrosis and developed effective medications.

References

  1. ↑ Joe Carlson (December 16, 2011). "Vertex names Leiden incoming CEO". Modern Healthcare.
  2. ↑ "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals Incorporated's Board of Directors". Biospace. July 8, 2009.
  3. ↑ "Jeffrey "Jeff" Leiden Chairman/President/CEO, Vertex Pharmaceuticals Inc". Bloomberg L.P. Retrieved May 12, 2018.
  4. 1 2 3 "First Rounders podcast: Jeffrey Leiden". Nature Biotechnology. 36 (3): 224. 2018-03-06. doi: 10.1038/nbt.4087 . ISSN   1546-1696. PMID   29509728.
  5. ↑ Arsenio Oloroso Jr. (September 24, 1994). "Jeffrey M. Leiden Section Chief of Cardiology University of Chicago Medical Center". Crain's Chicago Business.
  6. ↑ "Medicine on the Midway – Spring 2019". issuu. Retrieved 2019-07-02.
  7. 1 2 3 4 "Executive Profile Jeffrey Marc Leiden". Bloomberg L.P. Retrieved May 11, 2018.
  8. ↑ Hoffman, Michelle (December 6, 1991). "Putting new muscle into gene therapy". Science . 254 (5037): 1455–1456. Bibcode:1991Sci...254.1455H. doi:10.1126/science.1962203. PMID   1962203.
  9. ↑ Emily Mullin. "Jeffrey Leiden—Vertex Pharmaceuticals". FierceBiotech. Retrieved May 10, 2018.
  10. ↑ "Ins and Outs of Cardiovascular Gene Therapy; Cardiogene: The Insuide; Eurogene: The Outside". BioCentury. September 29, 1997.
  11. ↑ "Harvard cardiologist Jeffrey Leiden elected new chief scientific officer at Abbott Laboratories". Medscape. June 16, 2000.
  12. 1 2 "Jeffrey Leiden, M.D., Ph.D." Vertex Pharmaceuticals . Retrieved May 10, 2018.
  13. ↑ "Dr. Jeffrey Leiden Joins Clarus Ventures As Partner". Biospace. November 1, 2006.
  14. ↑ "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors". Evaluate. July 7, 2009.
  15. ↑ Matthew Herper (August 8, 2017). "For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another?". Forbes .
  16. ↑ Commissioner, Office of the (2019-10-24). "FDA approves new breakthrough therapy for cystic fibrosis". FDA. Retrieved 2019-10-25.
  17. ↑ "1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive". NPR.org. Retrieved 2021-02-23.
  18. ↑ "Vertex reveals promising data from first CRISPR-treated patients". PMLive. 2019-11-20. Retrieved 2021-02-23.
  19. ↑ Smith, Jonathan (2019-06-07). "CRISPR Therapeutics and Vertex Pharmaceuticals Seal Deal Worth up to €890M". Labiotech.eu. Retrieved 2021-02-23.
  20. ↑ "BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln". Reuters. 2018-04-17. Retrieved 2019-05-29.
  21. ↑ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
  22. ↑ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.
  23. ↑ "Vertex, NHS England and NICE finally reach agreement for Orkambi". PMLive. 2019-10-24. Retrieved 2019-10-25.
  24. ↑ "Vertex and the U.K. reach a deal for cystic fibrosis medicines". STAT. 2019-10-24. Retrieved 2019-10-25.
  25. ↑ "Cystic fibrosis drug deadlock 'must end'". 2019-02-04. Retrieved 2019-05-07.
  26. ↑ Bruce, Francesca. "Vertex Inks New Cystic Fibrosis Deals In Europe". Pink Sheet. Retrieved 3 April 2022.
  27. ↑ "Landmark NHS deal to open up access to life-changing cystic fibrosis drug". NHS. Retrieved 3 April 2022.
  28. ↑ Doler, Kathleen (16 July 2020). "How A Medical Brainiac CEO Turned Brilliance Into Billions".
  29. ↑ DeAngelis, Allison (25 July 2019). "Vertex CEO Jeff Leiden to step down". www.bizjournals.com. Retrieved 2019-07-31.
  30. ↑ "Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role". Endpoints News. Retrieved 2020-04-02.
  31. ↑ "Vertex Pharmaceuticals Incorporated Form 10-K" . Retrieved 3 April 2022.
  32. ↑ "Keynote Speakers". Massachusetts Institute of Technology. February 22, 2013.
  33. ↑ Pray, Leslie (August 14, 2007). Understanding the Benefits and Risks of Pharmaceuticals. National Academies Press. ISBN   9780309179768.
  34. ↑ "STEM Council Co-Chairs". Massachusetts Department of Higher Education. Retrieved May 20, 2018.
  35. ↑ Jennings, Katie. "This Smart Toilet Seat Might Save Your Life One Day". Forbes. Retrieved 2021-02-11.
  36. ↑ "Odyssey Therapeutics:News". odysseytx.com/news. 24 May 2022.
  37. ↑ "40 Under 40 historical archive". Crain's Chicago Business. July 9, 2014.
  38. ↑ "The American Society for Clinical Investigation" . Retrieved 2019-07-15.
  39. ↑ "EY Announces Winners for the Entrepreneur Of The Year® 2017 New England Award". Ernst & Young. June 28, 2017.
  40. ↑ "MassBio to Honor Dr. Jeffrey Leiden with Henri A. Termeer Innovative Leadership Award". MassBio. March 6, 2018.
  41. ↑ "With $500m initiative, Baker is a biotech holdout no longer". Boston Globe. June 21, 2017.
  42. ↑ "Meet the 2022 Boston Business Journal Power 50 Movement Makers". Boston Business Journal. 16 November 2022.
  43. ↑ "Meet the 2018 Boston Business Journal Power 50". Boston Business Journal. October 9, 2018.
  44. ↑ "Power List: The 100 Most Influential Bostonians". Boston Magazine. 28 April 2020. Retrieved 2020-05-05.
  45. ↑ "2018 New Englanders of the Year Announced". The New England Council. Retrieved November 18, 2018.
  46. ↑ "The 100 Most Influential People in Boston". Boston Magazine. April 24, 2018.
  47. ↑ "Leiden victorious in best biopharma CEO tally; Alles tops worst list". STAT. 2018-12-18. Retrieved 2019-07-02.
  48. ↑ "A Tribute to Jeffrey Leiden: Forbes Lifetime Achievement in BioPharma Award | 2020 Forbes Healthcare Summit". Forbes. Retrieved 2020-12-15.
  49. ↑ "Mass Digital Health Council". Mass Digital Health. Retrieved September 7, 2018.
  50. ↑ "Baker-Polito Administration Appoints STEM Advisory Council for 2017–2018". Mass.gov. Retrieved September 8, 2018.
  51. ↑ "America's Most Innovative Leaders". Forbes. Retrieved 2019-09-10.
  52. ↑ "Boston Symphony Orchestra concert program, Subscription Series, Season 139 (2019–2020), Week 6, page 5". collections.bso.org. Retrieved 2020-05-05.
  53. ↑ "MACP". macp. Retrieved 2021-03-16.
  54. ↑ "Jeffrey Leiden, M.D., Ph.D." Vertex.
  55. ↑ Bayer, Max (3 November 2022). "J.P. Morgan's new life sciences private equity arm will be hottest ticket at firm's upcoming conference". Fierce Biotech.
  56. ↑ "MACP". masscompetes.org.
  57. ↑ "Jeffrey Leiden, MD, PhD". Vrtx.com.
  58. ↑ "Bench to Bedside". Harvard Medical School. November 1, 2017.
  59. ↑ "The Future is Now: New Investments". Museum of Fine Arts, Boston . Retrieved May 24, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.